These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 15118983)

  • 1. Impact of highly active antiretroviral therapy on the spectrum of liver disease in HCV-HIV coinfection.
    Sterling RK; Wilson MS; Sanyal AJ; Luketic VA; Stravitz RT; Contos MJ; Mills AS; Shiffman ML
    Clin Gastroenterol Hepatol; 2004 May; 2(5):432-9. PubMed ID: 15118983
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liver injury and changes in hepatitis C Virus (HCV) RNA load associated with protease inhibitor-based antiretroviral therapy for treatment-naive HCV-HIV-coinfected patients: lopinavir-ritonavir versus nelfinavir.
    Sherman KE; Shire NJ; Cernohous P; Rouster SD; Omachi JH; Brun S; Da Silva B
    Clin Infect Dis; 2005 Oct; 41(8):1186-95. PubMed ID: 16163639
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of liver fibrosis on highly active antiretroviral therapy-associated hepatotoxicity in patients with HIV and hepatitis C virus coinfection.
    Aranzabal L; Casado JL; Moya J; Quereda C; Diz S; Moreno A; Moreno L; Antela A; Perez-Elias MJ; Dronda F; Marín A; Hernandez-Ranz F; Moreno A; Moreno S
    Clin Infect Dis; 2005 Feb; 40(4):588-93. PubMed ID: 15712082
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A study to investigate the impact of the initiation of highly active antiretroviral therapy on the hepatitis C virus viral load in HIV/HCV-coinfected patients.
    Mijch A; Sasadeusz J; Hellard M; Dunne M; McCaw R; Bowden S; Gowans EJ
    Antivir Ther; 2005; 10(2):277-84. PubMed ID: 15865222
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transient liver injury associated with the early recovery of HCV-specific T-cell responses and HCV rebound in HIV-1/HCV coinfected patients undergoing highly active antiretroviral therapy.
    Kang F; Chen W; Zhang X; Nie W; Fu J; Xu X; Zhao P; Zhang X; Li W; Wang FS; Zhang Z; Zhao M
    J Acquir Immune Defic Syndr; 2013 Feb; 62(2):135-42. PubMed ID: 23075912
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of HAART on liver histology of HIV/HCV coinfected patients.
    De Bona A; Sitia G; Uberti-Foppa C; Galli L; Ciuffreda D; Gallotta G; Paties C; Lazzarin A
    J Biol Regul Homeost Agents; 2003; 17(2):195-7. PubMed ID: 14518723
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk factors for severe hepatic injury after introduction of highly active antiretroviral therapy.
    Núñez M; Lana R; Mendoza JL; Martín-Carbonero L; Soriano V
    J Acquir Immune Defic Syndr; 2001 Aug; 27(5):426-31. PubMed ID: 11511818
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.
    Antonucci G; Girardi E; Cozzi-Lepri A; Capobianchi MR; De Luca A; Puoti M; Petrelli E; Carnevale G; Rizzardini G; Grossi PA; Viganò P; Moioli MC; Carletti F; Solmone M; Ippolito G; Monforte AD; ;
    Clin Infect Dis; 2005 Jun; 40(12):e101-9. PubMed ID: 15909251
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors affecting liver fibrosis in human immunodeficiency virus-and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy.
    Benhamou Y; Di Martino V; Bochet M; Colombet G; Thibault V; Liou A; Katlama C; Poynard T;
    Hepatology; 2001 Aug; 34(2):283-7. PubMed ID: 11481613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between exposure to nevirapine and reduced liver fibrosis progression in patients with HIV and hepatitis C virus coinfection.
    Berenguer J; Bellón JM; Miralles P; Alvarez E; Castillo I; Cosín J; López JC; Sánchez Conde M; Padilla B; Resino S
    Clin Infect Dis; 2008 Jan; 46(1):137-43. PubMed ID: 18171229
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advanced liver fibrosis in HIV/HCV-coinfected patients on antiretroviral therapy.
    Fuster D; Planas R; Muga R; Ballesteros AL; Santos J; Tor J; Sirera G; Guardiola H; Salas A; Cabré E; Ojanguren I; Barluenga E; Rey-Joly C; Clotet B; Tural C
    AIDS Res Hum Retroviruses; 2004 Dec; 20(12):1293-7. PubMed ID: 15650421
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HCV genotype distribution among HIV co-infected individuals in Argentina: relationship with host and viral factors.
    Quarleri JF; Bolcic FM; Bouzas MB; Laufer N; Gómez Carrillo M; Mammana L; Kaufman S; Pérez H; Cahn P; Salomon H
    Acta Gastroenterol Latinoam; 2007 Jun; 37(2):76-83. PubMed ID: 17684937
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impaired recovery of CD4+ cell counts following highly active antiretroviral therapy in drug-naïve patients coinfected with human immunodeficiency virus and hepatitis C virus.
    Macías J; Pineda JA; Lozano F; Corzo JE; Ramos A; León E; García-García JA; Fernández-Rivera J; Mira JA; Gómez-Mateos J
    Eur J Clin Microbiol Infect Dis; 2003 Nov; 22(11):675-80. PubMed ID: 14574616
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evolution of coinfection with human immunodeficiency virus and hepatitis C virus in patients treated with highly active antiretroviral therapy.
    Torre D; Tambini R; Cadario F; Barbarini G; Moroni M; Basilico C
    Clin Infect Dis; 2001 Nov; 33(9):1579-85. PubMed ID: 11588701
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Chronic hepatitis C in patients with HIV/HCV coinfection with high CD4+ lymphocytes count].
    Inglot M; Szymczak A; Gładysz A; Małyszczak K; Zalewska M
    Przegl Epidemiol; 2007; 61(3):535-43. PubMed ID: 18069391
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatitis C plasma viral load is associated with HCV genotype but not with HIV coinfection.
    Berger A; von Depka Prondzinski M; Doerr HW; Rabenau H; Weber B
    J Med Virol; 1996 Apr; 48(4):339-43. PubMed ID: 8699166
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatic steatosis in HIV-HCV coinfected patients receiving antiretroviral therapy is associated with HCV-related factors but not antiretrovirals.
    Martinez V; Ta TD; Mokhtari Z; Guiguet M; Miailhes P; Valantin MA; Charlotte F; Bertheau P; Molina JM; Katlama C; Caumes E
    BMC Res Notes; 2012 Jul; 5():180. PubMed ID: 22490728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effects of double and triple antiretroviral agents on the HCV viral load in patients coinfected with HIV and HCV].
    Gavazzi G; Richallet G; Morand P; Bouchard O; Bosseray A; Leclercq P; Micoud M
    Pathol Biol (Paris); 1998 Jun; 46(6):412-5. PubMed ID: 9769871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intrahepatic HCV RNA loads in 37 HIV-HCV co-infected patients with controlled HIV infection.
    Trimoulet P; Neau D; Le Bail B; Rullier A; Winnock M; Galperine T; Legrand E; Schvoerer E; Dupon M; Ragnaud JM; Bioulac-Sage P; Chêne G; Fleury H; Lafon ME
    J Med Virol; 2002 Jun; 67(2):143-51. PubMed ID: 11992575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Associations between lipodystrophy or antiretroviral medications and cirrhosis in patients with HIV infection or HIV/HCV coinfection.
    Ioannou GN; Bryson CL; Weiss NS; Boyko EJ
    Eur J Gastroenterol Hepatol; 2015 May; 27(5):577-84. PubMed ID: 25769096
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.